



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/031,353

04/11/2002

Edward S. Yeung

215390

6921

23460

7590

11/02/2005

LEYDIG VOIT & MAYER, LTD  
TWO PRUDENTIAL PLAZA, SUITE 4900  
180 NORTH STETSON AVENUE  
CHICAGO, IL 60601-6780

EXAMINER

STOCK JR, GORDON J

ART UNIT

PAPER NUMBER

2877

DATE MAILED: 11/02/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No. 10/031,353	Applicant(s) YEUNG ET AL.	
	Examiner Gordon J. Stock	Art Unit 2877	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 04 August 2005 and 22 August 2005.
- 2a) ☐ This action is FINAL.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1,3-23,57-65 and 67-91 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,3-23,57-65 and 67-91 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 11 April 2002 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                        | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____   | 6) <input type="checkbox"/> Other: _____                                    |

## DETAILED ACTION

### *Continued Examination Under 37 CFR 1.114*

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on August 4, 2005 has been entered.

### *Claim Rejections - 35 USC § 103*

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
3. **Claims 1, 3-8, 10-13, 15-22, 58, 60-65, 67-72, 74-76, 78-84, 86, 88-91** are rejected under 35 U.S.C. 103(a) as being unpatentable over **Simpson et al. (6,485,625)**—previously cited in view of **Stapleton (5,188,963)**—previously cited.

As to **claims 1, 3-8, 10-13, 15-18**, Simpson discloses the following: subjecting a sample comprising multiple molecules, at least two molecules are labeled to electrophoresis since four different fragments are labeled; imaging the mobility of each labeled molecule over time by detecting the position of the label over time; dispersing the imaging by a transmission grating; determining the electrophoretic mobility and the molecular spectrum; distinguishing molecules; at least four molecules are a nucleic acid and/or protein detectably labeled with a fluorescent dye; at least one small molecule may be a Sanger sequencing reaction fragment; said sample comprises a buffer; the at least two molecules with label has fluorescence induced by a laser; the fluorescence is focused on the imaging means; using an intensified CCD camera, TE/CCD

Art Unit: 2877

1023E detector from Princeton Instruments Inc.; laser filters are positioned in front of said imaging means; multiframe method is used; the mobility is imaged in less than about 5 milliseconds, 4000 frames per .1 second; at least one molecule is at a concentration of at least about 1 copy per milliliter, .5 microliters of sample was analyzed was loaded into the gel. (Figs. 1, 2a, 2b, 3, 11-13, 14a, 14b, 17(1), 17(2), 18a, 18b; col. 5, lines 20-30 and 50-67; col. 6, lines 1-15 and 45-55; col. 7, lines 5-20 and 60-67; col. 8, lines 130; col. 9, lines 60-65; col. 10, lines 15-65; cols. 11-12; cols. 31-32; col. 40, lines 15-55). And Simpson does disclose a sieving matrix (col. 19, lines 60-67). And discloses at least two molecules distinguished from spectral analysis (Figs. 17-19)

Simpson is silent concerning no amplification. Stapleton in a device for processing specimens for nucleic acid analysis teaches the equivalence of sample preparation with no amplification but with hybridization prior to electrophoresis and detection of particular fluorophores (Fig. 9). Therefore, it would be obvious to one of ordinary skill in the art at the time the invention was made to have the sample hybridized prior to electrophoresis and optical detection, for hybridization as a sample preparation is an art recognized equivalent to amplification as a sample preparation for electrophoresis with optical detection. In addition, Stapleton teaches that no amplification may be used for less complex samples (col. 18, lines 19-25). Therefore, it would be obvious to one of ordinary skill in the art at the time the invention was made to also have simpler samples not amplified prior to electrophoresis in order to distinguish between less complex samples such as from bacteria and to save time from not having to prep the sample for hybridization and/or amplification.

As for **claims 21, 22, 58, 60-62, 83, 84, 86, 88 and 89** Simpson discloses the following system: an electrophoretic sample channel; a monochromatic light source that irradiates sample; imaging means; a transmission grating; a lens between said light source and sample for focusing light; imaging means is an intensified CCD camera, TE/CCD 1023E detector; at least one filter, a laser filter; imaging means images 4000 frames per .1 second (Figs. 1, 2a, 2b, 3, 11-13, 14a, 14b, 17(1), 17(2), 18a, 18b; col. 5, lines 20-30 and 50-67; col. 6, lines 1-15 and 45-55; col. 7, lines 5-20 and 60-67; col. 8, lines 1-30; col. 9, lines 60-65; col. 10, lines 10-65; cols. 11-12; cols. 31-32; col. 40, lines 15-55). And discloses at least two molecules distinguished from spectral analysis (Figs. 17-19)

Simpson is silent concerning no amplification. Stapleton in a device for processing specimens for nucleic acid analysis teaches the equivalence of sample preparation with no amplification but with hybridization prior to electrophoresis and detection of particular fluorophores (Fig. 9). Therefore, it would be obvious to one of ordinary skill in the art at the time the invention was made to have the sample hybridized prior to electrophoresis and optical detection, for hybridization as a sample preparation is an art recognized equivalent to amplification as a sample preparation for electrophoresis with optical detection. In addition, Stapleton teaches that no amplification may be used for less complex samples (col. 18, lines 19-25). Therefore, it would be obvious to one of ordinary skill in the art at the time the invention was made to also have simpler samples not amplified prior to electrophoresis in order to distinguish between less complex samples such as from bacteria and to save time from not having to prep the sample for hybridization and/or amplification.

As to **claims 65, 67-72, 74-76, 78-80**, Simpson discloses the following: introducing a sample comprising multiple molecules in free solution at least two are detectably labeled into a sample channel for four different dyes are used for four different base fragments; imaging the position of labeled molecule and dispersing image by a transmission grating; determining molecular spectrum; distinguishing at least one molecule; the molecule may be a labeled nucleic acid or protein; at least one small molecule may be a Sanger sequencing reaction fragment; sample comprises a buffer; the labeled sample is fluoresced by a laser; there is focusing of the fluorescent label on imaging means; an intensified CCD camera, TE/CCD 1023E detector, comprises the imaging means; a laser filter is positioned before the imaging means; imaging happens in 4000 frames per .1 second; .5 microliters of sample is analyzed (Figs. 1, 2a, 2b, 3, 11-13, 14a, 14b, 17(1), 17(2), 18a, 18b; col. 5, lines 20-30 and 50-67; col. 6, lines 1-15 and 45-55; col. 7, lines 5-20 and 60-67; col. 8, lines 1-30; col. 9, lines 60-65; col. 10, lines 10-65; cols. 11-12; cols. 31-32; col. 40, lines 15-55). And discloses at least two molecules distinguished from spectral analysis (Figs. 17-19)

Simpson is silent concerning no amplification. Stapleton in a device for processing specimens for nucleic acid analysis teaches the equivalence of sample preparation with no amplification but with hybridization prior to electrophoresis and detection of particular fluorophores (Fig. 9). Therefore, it would be obvious to one of ordinary skill in the art at the time the invention was made to have the sample hybridized prior to electrophoresis and optical detection, for hybridization as a sample preparation is an art recognized equivalent to amplification as a sample preparation for electrophoresis with optical detection. In addition, Stapleton teaches that no amplification may be used for less complex samples (col. 18, lines 19-

Art Unit: 2877

25). Therefore, it would be obvious to one of ordinary skill in the art at the time the invention was made to also have simpler samples not amplified prior to electrophoresis in order to distinguish between less complex samples such as from bacteria and to save time from not having to prep the sample for hybridization and/or amplification.

As to **claims 19, 20, 81, and 82**, Simpson in view of Stapleton discloses everything as above (see **claims 1 and 65**). As for the particular acquisition rates Simpson is silent. However, the acquisition rate depends on several factors such as electrode voltage, electrophoretic mobility, frame rate, image processing rate, and fluorescence. This acquisition rate would be considered an optimized value. Simpson discloses the claimed invention except for the particular acquisition rates. It would have been obvious to one having ordinary skill in the art at the time of the invention was made to have the particular acquisition rates, since it has been held that discovering an optimum value of a result effective variable involves only routine skill in the art. In re Boesch, 617 F.2d 272, 205 USPQ 215 (CCPA 1980)

As to **claims 63, 64, 90, and 91**, Simpson in view of Stapleton discloses everything as above (see **claims 21 and 83**). As for the particular acquisition rates Simpson is silent. However, the acquisition rate depends on several factors such as electrode voltage, electrophoretic mobility, frame rate, image processing rate, and fluorescence. This acquisition rate would be considered an optimized value. Simpson discloses the claimed invention except for the particular acquisition rates. It would have been obvious to one having ordinary skill in the art at the time of the invention was made to have the particular acquisition rates, since it has been held that discovering an optimum value of a result effective variable involves only routine skill in the art. In re Boesch, 617 F.2d 272, 205 USPQ 215 (CCPA 1980)

Art Unit: 2877

4. **Claims 9 and 73** are rejected under 35 U.S.C. 103(a) as being unpatentable over **Simpson et al. (6,485,625)—previously cited** in view of **Stapleton (5,188,963)—previously cited** further in view of **Schwartz et al. (6,221,592) and Chu (5,215,883)—both previously cited**.

As to **claims 9 and 73**, Simpson in view of Stapleton discloses everything as above (see **claims 8 and 72**). Simpson is silent concerning photobleaching. However, Schwartz in nucleic acid sequencing teaches photobleaching for eliminating fluorescence signals between cycles and to eliminate bulky moieties after they have served their purpose (col. 33, lines 55-67). In addition, Chu in electrophoretic system teaches photobleaching for demarcation of areas for detection (col. 8, lines 10-50). Therefore, it would be obvious to one of ordinary skill in the art at the time the invention was made to photobleach the buffer in order to eliminate possible fluorescent signals after certain substituents have served their purpose and/or possibly to demarcate areas for detection.

5. **Claims 14 and 77** are rejected under 35 U.S.C. 103(a) as being unpatentable over **Simpson et al. (6,485,625)—previously cited** in view of **Stapleton (5,188,963)—previously cited** further in view of **Yguerabide et al. (6,586,193)—previously cited** and **Hayashizaki et al. (6,120,667)—previously cited**.

As to **claims 14 and 77**, Simpson in view of Stapleton discloses everything as above (see **claims 12 and 75**). Simpson is silent concerning a pinhole and equilateral prism. Yguerabide teaches in an analyte assay using labels that equilateral prisms are used to enhance to signal to noise (col. 59, lines 20-45). Therefore, it would be obvious to one of ordinary skill in the art at the time the invention was made to have the system comprise an equilateral prism to enhance



Art Unit: 2877

signal to noise of the system. And Hayashizaki in an electrophoresis apparatus teaches a pinhole to limit the detection field (col. 7, lines 15-25). Therefore, it would be obvious to one of ordinary skill in the art at the time the invention was made to have the system comprise a pinhole in order to limit the detection field.

6. **Claims 23, 57, and 85** are rejected under 35 U.S.C. 103(a) as being unpatentable over **Simpson et al. (6,485,625)**—previously cited in view of **Stapleton (5,188,963)**—previously cited further in view of **Yguerabide et al. (6,586,193)** and **Hayashizaki et al. (6,120,667)**—both previously cited.

As to **claims 23, 57, and 85**, Simpson in view of Stapleton discloses everything as above (see **claims 21, 22, and 84**). Simpson is silent concerning a pinhole and equilateral prism. Yguerabide teaches in an analyte assay using labels that equilateral prisms are used to enhance to signal to noise (col. 59, lines 20-45). Therefore, it would be obvious to one skilled in the art to have the system comprise an equilateral prism to enhance signal to noise of the system. Hayashizaki in an electrophoresis apparatus teaches a pinhole to limit the detection field (col. 7, lines 15-25). Therefore, it would be obvious to one skilled in the art to have the system comprise a pinhole in order to limit the detection field.

7. **Claims 59 and 87** are rejected under 35 U.S.C. 103(a) as being unpatentable over **Simpson et al. (6,485,625)**—previously cited in view of **Stapleton (5,188,963)**—previously cited further in evidence of **Brumley et al. (5,538,613)**—previously cited.

As for **claims 59 and 87**, Simpson discloses everything as above (see **claims 58 and 86**). In addition, Simpson discloses objective lenses (col. 12, lines 1-40). In addition, Brumley in an electrophoresis analyzer teaches using a microscope objective for focusing (Fig. 1).

***Response to Arguments***

8. Applicant's arguments with respect to the claims have been considered but are moot in view of the new ground(s) of rejection. However, Examiner will address the arguments sans the Craighead patent. As for the Simpson patent or the Stapleton not disclosing or suggesting a method that can distinguish at least two molecules simultaneously, Examiner disagrees. Simpson suggests at least four different base fragments being analyzed (col. 10, lines 10-20) and demonstrates multiple molecules being analyzed from multiple spectrum being gathered simultaneously (Figs. 17-18). In **claim 65** 'at least two molecules simultaneously' does not preclude a plurality of identical molecules such as in a sample comprising .5 microliters nor does it preclude four different base fragments; in claim 1 "at least two molecules individually" does not preclude at least four different base fragments as suggested in Figs. 17-18 nor a plurality of differing base fragments in a sample comprising micromolar amounts of molecular species such as in a .5 microliter sample (col. 40, lines 35-40). In **claims 1, 21, 65, and 83**, "at least two detectably labeled molecules" does not preclude a plurality of identical molecules such as in a sample comprising .5 microliters nor does it preclude four different base fragments being analyzed. Examiner would like to comment on the use of 'optionally' in **claims 1 and 21**. Simpson discloses the limitations following the word 'optionally;' however, the Examiner does interpret the word 'optionally' as 'not necessarily having' the limitations following the word, 'optionally.' In addition, the Examiner interprets the term 'thereby' as not requiring the steps following it and therefore, the statements with 'thereby' do not limit the scope of the claim to "distinguishing at least two molecules individually in a sample comprising multiple molecules"

Art Unit: 2877

as in lines 13-14 of **claim 1** and “distinguishing at least two molecules simultaneously in a sample comprising multiple molecules” as in lines 14-15 of **claim 65**. See MPEP 2106 II. C.

***Fax/Telephone Numbers***

If the applicant wishes to send a fax dealing with either a proposed amendment or a discussion with a phone interview, then the fax should:

1) Contain either a statement “DRAFT” or “PROPOSED AMENDMENT” on the fax cover sheet; and

2) Should be unsigned by the attorney or agent.

This will ensure that it will not be entered into the case and will be forwarded to the examiner as quickly as possible.

*Papers related to the application may be submitted to Group 2800 by Fax transmission. Papers should be faxed to Group 2800 via the PTO Fax machine located in Crystal Plaza 4. The form of such papers must conform to the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CP4 Fax Machine number is: (571) 273-8300*

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gordon J. Stock whose telephone number is (571) 272-2431.

The examiner can normally be reached on Monday-Friday, 10:00 a.m. - 6:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gregory J. Toatley, Jr., can be reached at 571-272-2800 ext 77.


Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Art Unit: 2877

system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private Pair system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
gs

October 30, 2005

  
Gregory M. Tooley, Jr.  
Supervisory Patent Examiner  
Art Unit 2877  
31 Oct 05